Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I BT8009 safety and pharmacokinetics study in Japanese patients with Nectin-4–expressing advanced solid tumors
jRCT2031240238Phase 1Active, not recruiting
- Sponsor
- Bicycle Therapeutics
- Start
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of zelenectide pevedotin and pembrolizumab in transitional cell carcinoma (TCC), pancreatic cancer (PC), breast cancer and 5 more (4 arms), sponsored by Bicycle Therapeutics. Primary endpoints: Adverse events, Laboratory abnormalities and 2 more. Started Aug 2024; status: active, not recruiting.
02
Drugs
zelenectide pevedotinpembrolizumab
03
Conditions
transitional cell carcinoma (TCC)pancreatic cancer (PC)breast cancernon-small cell lung cancer (NSCLC)gastric cancer (GC)
Beyond the preview
Go deeper on jRCT2031240238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240238.